CA3120872A1 - Neuroactive steroids and their methods of use - Google Patents

Neuroactive steroids and their methods of use Download PDF

Info

Publication number
CA3120872A1
CA3120872A1 CA3120872A CA3120872A CA3120872A1 CA 3120872 A1 CA3120872 A1 CA 3120872A1 CA 3120872 A CA3120872 A CA 3120872A CA 3120872 A CA3120872 A CA 3120872A CA 3120872 A1 CA3120872 A1 CA 3120872A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
compound
alkyl
independently hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3120872A
Other languages
English (en)
French (fr)
Inventor
Maria Jesus Blanco-Pillado
Francesco G. Salituro
Marshall Lee MORINGSTAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics Inc
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of CA3120872A1 publication Critical patent/CA3120872A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3120872A 2018-12-05 2019-12-05 Neuroactive steroids and their methods of use Pending CA3120872A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862775470P 2018-12-05 2018-12-05
US62/775,470 2018-12-05
PCT/US2019/064692 WO2020118060A1 (en) 2018-12-05 2019-12-05 Neuroactive steroids and their methods of use

Publications (1)

Publication Number Publication Date
CA3120872A1 true CA3120872A1 (en) 2020-06-11

Family

ID=69006056

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3120872A Pending CA3120872A1 (en) 2018-12-05 2019-12-05 Neuroactive steroids and their methods of use

Country Status (14)

Country Link
US (8) US20230322846A9 (cg-RX-API-DMAC7.html)
EP (1) EP3902818A1 (cg-RX-API-DMAC7.html)
JP (3) JP7539378B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250174100A (cg-RX-API-DMAC7.html)
CN (1) CN113383004A (cg-RX-API-DMAC7.html)
AR (1) AR117264A1 (cg-RX-API-DMAC7.html)
AU (3) AU2019392680B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010996A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120872A1 (cg-RX-API-DMAC7.html)
IL (3) IL312610B2 (cg-RX-API-DMAC7.html)
MA (1) MA54594A (cg-RX-API-DMAC7.html)
MX (4) MX2021006618A (cg-RX-API-DMAC7.html)
TW (3) TWI874337B (cg-RX-API-DMAC7.html)
WO (1) WO2020118060A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CA3086299A1 (en) * 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
JP7538040B2 (ja) 2018-01-12 2024-08-21 セージ セラピューティクス, インコーポレイテッド CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物
TWI848034B (zh) * 2018-12-21 2024-07-11 美商賽吉醫療公司 神經活性類固醇及其組合物
JP7670626B2 (ja) * 2019-05-31 2025-04-30 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド及びその組成物
JP7787635B2 (ja) * 2019-06-27 2025-12-17 セージ セラピューティクス, エルエルシー Cns障害を治療するための組成物及び方法
CA3143545A1 (en) * 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compounds for treating cns disorders
AU2021238346A1 (en) 2020-03-18 2022-09-29 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
CN112679571A (zh) * 2020-12-24 2021-04-20 广西壮族自治区中国科学院广西植物研究所 一种罗汉果醇衍生物单体、其制备方法及应用
EP4392432A2 (en) * 2021-08-25 2024-07-03 Sage Therapeutics, Inc. Positive nmda-modulating compounds and methods of use thereof
CN115974950A (zh) * 2022-12-23 2023-04-18 上海彩迩文生化科技有限公司 一种3-烷基化的甾体中间体及其制备和应用
CN120936616A (zh) 2023-03-14 2025-11-11 库里亚西班牙公司 用于制备3α-羟基-3β-烷基类固醇的方法和中间体
WO2024197317A2 (en) * 2023-03-23 2024-09-26 Emory University Neurosteroids and prodrugs thereof
CN119529013B (zh) * 2024-11-25 2025-11-07 湖南新合新生物医药有限公司 一种祖拉诺龙中间体的合成方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2969M (fr) * 1963-05-22 1964-11-30 Roussel Uclaf Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale.
ES432106A1 (es) 1973-11-30 1976-11-01 Schering Ag Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
IL48628A0 (en) 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
US4060295A (en) 1976-03-15 1977-11-29 Molex Incorporated Zero insertion force printed circuit board edge connector assembly
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
BR9509764A (pt) * 1994-11-23 1998-07-07 Cocensys Inc Série androstano e pregnano para modulação alostérica de receptor de gaba
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
FR2967914A1 (fr) 2010-11-29 2012-06-01 Centre Nat Rech Scient Composes inhibiteurs d'interactions proteine-proteine ciblant les proteines kinases et leurs applications biologiques
EP4717314A2 (en) 2011-10-14 2026-04-01 Sage Therapeutics, LLC 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US9725481B2 (en) * 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
MY190408A (en) 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
WO2017049044A1 (en) 2015-09-16 2017-03-23 Bartolucci Giampiero Ursodeoxycholic acid and brain disorders
WO2017187343A2 (en) 2016-04-29 2017-11-02 Thome Kreutz Fernando Nanoemulsions and methods for cancer therapy
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
CN108727453A (zh) 2017-04-20 2018-11-02 华东理工大学 新型pd-1抑制剂及其应用
EP3728285B1 (en) 2017-12-22 2026-04-08 Sage Therapeutics, LLC Compositions and methods for treating cns disorders
US20200384003A1 (en) 2017-12-29 2020-12-10 Shanghai Lanmu Chemicals Co., Ltd. Triterpenoid-containing pharmaceutical composition and use thereof
US12139508B2 (en) 2018-02-11 2024-11-12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
JP2022501348A (ja) 2018-09-19 2022-01-06 モデルナティエックス インコーポレイテッドModernaTX, Inc. ステロール類似体及びその使用
TWI848034B (zh) 2018-12-21 2024-07-11 美商賽吉醫療公司 神經活性類固醇及其組合物
WO2020210117A1 (en) 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof
WO2020210116A1 (en) 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof
US20220226350A1 (en) 2019-05-30 2022-07-21 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド及びその組成物
CA3143545A1 (en) 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compounds for treating cns disorders
US20220396597A1 (en) 2019-10-25 2022-12-15 Washington University Nmdar inhibiting agents and gabaar potentiating agents and uses thereof
CN115768781A (zh) 2020-06-24 2023-03-07 萨奇治疗股份有限公司 3.α.-羟基,17.β.-C(O)-N-芳基取代的神经活性类固醇及其组合物

Also Published As

Publication number Publication date
MX2021006618A (es) 2021-09-23
US11970514B2 (en) 2024-04-30
AU2019392680A1 (en) 2021-06-10
TW202521127A (zh) 2025-06-01
IL312610A (en) 2024-07-01
MX2024004790A (es) 2024-05-09
IL283629A (en) 2021-07-29
AR117264A1 (es) 2021-07-21
IL312611B2 (en) 2025-09-01
US20230322847A1 (en) 2023-10-12
JP2024105504A (ja) 2024-08-06
KR20250174100A (ko) 2025-12-11
BR112021010996A2 (pt) 2021-08-31
JP7539378B2 (ja) 2024-08-23
US20230322846A9 (en) 2023-10-12
US20240336648A1 (en) 2024-10-10
US20230322848A1 (en) 2023-10-12
TW202039528A (zh) 2020-11-01
JP2025134803A (ja) 2025-09-17
US11999765B2 (en) 2024-06-04
US20230046825A1 (en) 2023-02-16
US20250154194A1 (en) 2025-05-15
MA54594A (fr) 2022-04-06
AU2025203487A1 (en) 2025-05-29
AU2025203485A1 (en) 2025-05-29
US12264177B2 (en) 2025-04-01
US11912738B2 (en) 2024-02-27
TWI874337B (zh) 2025-03-01
IL312611A (en) 2024-07-01
JP7720948B2 (ja) 2025-08-08
US12252509B2 (en) 2025-03-18
CN113383004A (zh) 2021-09-10
US20240343756A1 (en) 2024-10-17
US20240309042A1 (en) 2024-09-19
MX2024004789A (es) 2024-05-09
IL283629B1 (en) 2025-11-01
WO2020118060A1 (en) 2020-06-11
EP3902818A1 (en) 2021-11-03
MX2024004788A (es) 2024-05-09
IL312610B1 (en) 2026-01-01
US12410210B2 (en) 2025-09-09
US20230322849A1 (en) 2023-10-12
KR20210112318A (ko) 2021-09-14
TWI924370B (zh) 2026-05-01
KR102892974B1 (ko) 2025-11-28
IL312611B1 (en) 2025-05-01
IL283629B2 (en) 2026-03-01
IL312610B2 (en) 2026-05-01
AU2019392680B2 (en) 2025-07-10
TW202521129A (zh) 2025-06-01
JP2022510683A (ja) 2022-01-27

Similar Documents

Publication Publication Date Title
US12264177B2 (en) Neuroactive steroids and their methods of use
CA3086189A1 (en) Compositions and methods for treating cns disorders
CA3175324A1 (en) Neuroactive steroids and their methods of use
AU2025200422A1 (en) Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders
RU2830163C2 (ru) Нейроактивные стероиды и способы их применения
EP4406602A2 (en) C7, c12, and c16 substituted neuroactive steroids and their methods of use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231205

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241111

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241111

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241111

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250221

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250620

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250626

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250728

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250728

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251107

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20260203

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260514

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260525

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260525